China Resources Pharmaceutical Group Limited (CHINARES PHARMA) reported that its approximately 28%-owned subsidiary, Tasly Pharmaceutical Group Co., Ltd., released unaudited results for the three months ended 31 March 2026.

Key Operating Metrics • Revenue reached RMB 2.16 billion, up 5.35% from RMB 2.05 billion a year earlier, reflecting continued sales momentum. • Net profit rose to RMB 0.36 billion, a year-on-year increase of 9.78%, outpacing revenue growth and indicating improved operating leverage.

Balance-Sheet Snapshot (as at 31 March 2026) • Total assets: RMB 15.69 billion, up 2.30% from end-2025. • Total liabilities: RMB 2.79 billion, essentially unchanged from end-2025. • Owner’s equity: RMB 12.91 billion, expanding by 2.85% in three months, driven mainly by retained earnings.

Cash Flow • Net cash outflow for the quarter widened to RMB 0.82 billion, versus RMB 0.08 billion in the prior-year period. • Cash and cash equivalents stood at RMB 0.60 billion at quarter-end, down from RMB 0.74 billion a year earlier.

Compliance Note The figures are prepared under PRC GAAP and remain unaudited. They pertain solely to Tasly Pharmaceutical and do not represent the consolidated performance of CHINARES PHARMA. Shareholders and potential investors are advised to exercise caution when interpreting these results.